EP
IRMD icon

Eversept Partners’s iRadimed IRMD Stock Holding History

Eversept Partners’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-17,608
Closed -$365K – 71
2018
Q2 		$365K Sell
17,608
-33,451
-66% -$591K 0.17% 67
2018
Q1 		$735K Hold
51,059
– – 0.34% 43
2017
Q4 		$774K Buy
+51,059
New +$649K 0.45% 35

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
NA
Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Eversept Partners's IRMD Position: Q3 2018 in Review

Eversept Partners sold out of iRadimed (IRMD) in Q3 2018, closing a stake of 17,608 shares — an estimated $365K sold.

Eversept Partners first reported a position in IRMD in Q4 2017 and held it in 3 quarters. The position peaked at $774K in Q4 2017. 68 funds tracked by Wall St. Rank hold IRMD as of Q3 2018.

  • Eversept Partners reported no remaining iRadimed position as of Q3 2018 after selling out during the quarter.
  • Eversept Partners sold 17,608 iRadimed shares in Q3 2018, an estimated $365K.
  • Eversept Partners first reported a position in iRadimed in Q4 2017 and held it in 3 quarters.
  • Eversept Partners's iRadimed position peaked at $774K in Q4 2017.
  • 68 funds tracked by Wall St. Rank held iRadimed as of Q3 2018.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.